Abstract:Background The International IgA Nephropathy (IgAN) Network developed and validated two prognostic prediction models for IgAN, one incorporating a race parameter. These models could anticipate the risk of a 50% reduction in estimated glomerular filtration rate (eGFR) or progression to end-stage renal disease (ESRD) subsequent to an IgAN diagnosis via renal biopsy. This investigation aimed to validate the International IgA Nephropathy Prediction Tool (IIgANPT) within a contemporary Chinese cohort.
What problem does this paper attempt to address?
The main aim of this paper is to externally validate an international prognostic model for IgA nephropathy (IgAN) — the International IgA Nephropathy Prediction Tool (IIgANPT). The research team hopes to evaluate the applicability and accuracy of this model in a contemporary Chinese patient cohort through this validation work.
Specifically, the researchers included 185 patients diagnosed with IgAN via renal biopsy at the Kidney Disease Center of the Second Affiliated Hospital of Nanjing Medical University between 2012 and 2021. The prognostic risk of these patients was assessed using the IIgANPT formula, with the primary outcome measures being a 50% decline in estimated glomerular filtration rate (eGFR) or progression to end-stage renal disease (ESRD). To evaluate the model's performance, the researchers employed various statistical methods, including receiver operating characteristic (ROC) curves, subgroup survival analysis, calibration plots, and decision curve analysis.
The results indicated that both prediction models, whether or not they included racial parameters, demonstrated good discrimination, with the area under the ROC curve at 5 years being 0.882 and 0.878, respectively. Additionally, the models showed good calibration, and the decision curve analysis indicated potential clinical utility. Overall, the study concluded that these two prognostic risk assessment models have significant discriminatory power, reasonable calibration, and acceptable clinical utility for IgAN patients. This provides clinicians with a powerful tool to assess patient risk and may help guide treatment strategies.